The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis.
Pirkko-Liisa Irmeli Kellokumpu-Lehtinen
Consultant or Advisory Role - Roche; Sanofi
Honoraria - GlaxoSmithKline; Lilly; Roche; Sanofi
Research Funding - Sanofi
Ulrika Harmenberg
No relevant relationships to disclose
Petteri Hervonen
Consultant or Advisory Role - Janssen-Cilag
Honoraria - Bayer; Janssen-Cilag
Timo K. Joensuu
Honoraria - Sanofi
Raymond S. McDermott
Honoraria - GlaxoSmithKline; Pfizer
Claes Ginman
No relevant relationships to disclose
Marjaana Luukkaa
Consultant or Advisory Role - Janssen-Cilag (I)
Paul Nyandoto
No relevant relationships to disclose
Akseli Hemminki
No relevant relationships to disclose
Sten Nilsson
No relevant relationships to disclose
John McCaffrey
No relevant relationships to disclose
Raija Asola
No relevant relationships to disclose
Taina Turpeenniemi Hujanen
No relevant relationships to disclose
Fredrik Laestadius
No relevant relationships to disclose
Tiina Tasmuth
No relevant relationships to disclose
Katinka Sandberg
No relevant relationships to disclose
Maccon M. Keane
No relevant relationships to disclose
Ilari Lehtinen
No relevant relationships to disclose
Tiina Luukkaala
No relevant relationships to disclose
Heikki Joensuu
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi